Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Sep 12, 2022 3:22pm
166 Views
Post# 34957507

RE:PUMP and DUMP ?

RE:PUMP and DUMP ?

Back in July they report their Partial Response patient, other efficacy signs in 1a, the program moving on to phase 1b, an incomplete but benign looking safety profile at the the RP2D. They also reported sorting out some near/mid term financing issues. All that looked like significant milestones. It generated less volume in the US than today and less SP reaction.( the volume today isn't massive or massively greater than back in July)

What's going on?

Is the world upside down? Am I upside down? Have they actually primed the market to react to good news? Has ESMO got people googling cancer atm?

It doesn't quite make sense to me.


FredTheVoice wrote: Muslix, it seems that your theory was false.......

Lets see what tomorrow brings.

Just read that a poster sold at these ridiculous price.......WOW

FTV

 

<< Previous
Bullboard Posts
Next >>